WebMar 6, 2015 · CTH522 was compared with rMOMP in a genital SvD challenge experiment. Compared with vaccination with rMOMP, CTH522 induced high levels of neutralizing antibodies against the 4 serovars SvD, SvE, SvF, and SvG (Figure 6 A ) and provided significant protection at both early and later time points (Figure 6 B ). WebOct 1, 2024 · Both CTH522:CAF01 and CTH522:AH induced anti-CTH522 IgG seroconversion in 15 (100%) of 15 participants after five immunisations, whereas no participants in the placebo group seroconverted. CTH522:CAF01 showed accelerated seroconversion, increased IgG titres, an enhanced mucosal antibody profile, and a more …
Novel Chlamydia Vaccine Demonstrated Immunogenicity in …
WebAug 19, 2024 · The vaccine is based on a recombinant protein subunit (CTH522) and evaluated in a prime—boost immunization schedule. The study enrolled 35 female participants aged 19-45 years. The participants were randomized 3:3:1 to receive either: CTH522 adjuvanted with CAF01 liposomes (CTH522:CAF01), CTH522 adjuvanted with … WebNov 23, 2024 · The immunization antigens included the recombinant protein antigen CTH522 adjuvanted with CAF01 or aluminium hydroxide, MOMP DNA antigen and … howard woehrle obituary
Safety and Immunogenicity of a Chlamydia Vaccine CTH522
WebFeb 6, 2024 · Meanwhile the fast gelation at body temperature together with rapid antigen release should avoid CTH522 leakage by swallowing and increase the contact with sublingual tissue, thus promoting absorption. In vivo studies demonstrated that parenteral-sublingual prime-boost immunization, using CAF01 and OGEL as CTH522 vaccine … WebAug 13, 2024 · CTH522:CAF01 showed additional signs of better performance compared with CTH522:AH including an enhanced mucosal antibody profile that serves as first line of defence against the infection, and a ... WebJun 1, 2016 · Abraham S, Juel HB, Bang P, Cheeseman HM, Dohn RB, Cole T, Kristiansen MP, Korsholm KS, Lewis D, Olsen AW, McFarlane LR, Day S, Knudsen S, Moen K, Ruhwald M, Kromann I, Andersen P, Shattock RJ, Follmann F. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or … howard witt littelfuse